Protective effect of thioredoxin perfusion but not inhalation in warm ischemic-reperfused rat lungs

Redox Report

Volumn 14, Issue 2, 2009, Pages 75-81

  Zhang, Jitian ^a   Chen, Fengshi ^b   Nakamura, Takayuki ^b   Fujinaga, Takuji ^b   Aoyama, Akihiro ^a   Hamakawa, Hiroshi ^a   Sakai, Hiroaki ^a   Hoshino, Yuma ^c   Yodoi, Junji ^a   Wada, Hiromi ^a   Bando, Toru ^b   Nakamura, Hajime ^c  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Inhalation; Ischemia reperfusion injury; Lung transplantation; Oxidized rhTRX; Perfusion; rhTRX

Indexed keywords

ALBUMIN; HEMOGLOBIN; MERCAPTOALBUMIN; RECOMBINANT PROTEIN; THIOREDOXIN; UNCLASSIFIED DRUG;

AIRWAY RESISTANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD GAS; CONTROLLED STUDY; HEMOGLOBIN DETERMINATION; LUNG ARTERY PRESSURE; LUNG COMPLIANCE; LUNG FUNCTION; LUNG INJURY; LUNG ISCHEMIA; LUNG PERFUSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; TIDAL VOLUME; WEIGHT GAIN;

ADMINISTRATION, INHALATION; ANIMALS; HUMANS; LUNG; MALE; PERFUSION; RANDOM ALLOCATION; RATS; RATS, INBRED LEW; REPERFUSION INJURY; SERUM ALBUMIN; THIOREDOXINS;

RATTUS;

EID: 69249125028     PISSN: 13510002     EISSN: None     Source Type: Journal    
DOI: 10.1179/135100009X392511     Document Type: Article

References (33)

1. Holmgren A. Thioredoxin. Annu Rev Biochem 1985; 54: 237-271.
2. Nakamura H. Thioredoxin and its related molecules: Update 2005. Antioxid Redox Signal 2005; 7: 823-828.
3. Nakamura T, Nakamura H, Hoshino T, Ueda S, Wada H, Yodoi J. Redox regulation of lung inflammation by thioredoxin. Antioxid Redox Signal 2005; 7: 60-71.
4. Kondo N, Ishii Y, Kwon YW et al. Redox-sensing release of human thioredoxin from T lymphocytes with negative feedback loops. J Immunol 2004; 172: 442-448.
5. Nakamura H, Nakamura K, Yodoi J. Redox regulation of cellular activation. Annu Rev Immunol 1997; 15: 351-369.
6. Bertini R, Howard OM, Dong HF et al. Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. J Exp Med 1999; 189: 1783-1789.
7. Nakamura H, Herzenberg LA, Bai J et al. Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis. Proc Natl Acad Sci USA 2001; 98: 15143-15148.
8. Duncan SR. In: Norman DJ, Turka LA. (eds) Primer on transplantation, 2nd edn. Philadelphia, PA: American Society of Transplantation, 2001; 685-695.
9. Mora BN, Patterson GA. In: Baumgartner WA, Kasper E, Reitz B, Theodore J. (eds) Heart and lung transplantation, 2nd edn. Philadelphia, PA: WB Saunders, 2002; 142-154.
10. Fukuse T, Hirata T, Yokomise H et al. Attenuation of ischaemia reperfusion injury by human thioredoxin. Thorax 1995; 50: 387-391.
11. Yokomise H, Fukuse T, Hirata T et al. Effect of recombinant human adult T cell leukemia-derived factor on rat lung reperfusion injury. Respiration 1994; 61: 99-104.
12. Okubo K, Kosaka S, Isowa N et al. Amelioration of ischemia-reperfusion injury by human thioredoxin in rabbit lung. J Thorac Cardiovasc Surg 1997; 113: 1-9.
13. Yagi K, Liu C, Bando T et al. Inhibition of reperfusion injury by human thioredoxin (adult T-cell leukemia-derived factor) in canine lung transplantation. J Thorac Cardiovasc Surg 1994; 108: 913-921.
14. Nakamura T, Hoshino Y, Yamada A et al. Recombinant human thioredoxin-1 becomes oxidized in circulation and suppresses bleomycin-induced neutrophil recruitment in the rat airway. Free Radic Res 2007; 41: 1089-1098.
15. Mitsui A, Hirakawa H, Yodoi J. Reactive oxygen-reducing and protein-refolding activities of adult T cell leukemia-derived factor/ human thioredoxin. Biochem Biophys Res Commun 1992; 186: 1220-1226.
16. Chen F, Nakamura T, Fujinaga T et al. Protective effect of a nebulized beta(2)-adrenoreceptor agonist in warm ischemic-reperfused rat lungs. Ann Thorac Surg 2006; 82: 465-471.
17. Fujinaga T, Nakamura T, Fukuse T et al. Isoflurane inhalation after circulatory arrest protects against warm ischemia reperfusion injury of the lungs. Transplantation 2006; 82: 1168-1174
18. Nakamura T, Abu-Dahab R, Menger MD et al. Depletion of alveolar macrophages by clodronate-liposomes aggravates ischemia-reperfusion injury of the lung. J Heart Lung Transplant 2005; 24: 38-45.
19. Ueda S, Nakamura T, Yamada A et al. Recombinant human thioredoxin suppresses lipopolysaccharide-induced bronchoalveolar neutrophil infiltration in rat. Life Sci 2006; 79: 1170-1177.
20. Hayashi T, Suda K, Imai H, Era S. Simple and sensitive high-performance liquid chromatographic method for the investigation of dynamic changes in the redox state of rat serum albumin. J Chromatogr B 2002; 772: 139-146.
21. Takagi Y, Mitsui A, Nishiyama A et al. Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage. Proc Natl Acad Sci USA 1999; 96: 4131-4136.
22. Takagi Y, Tokime T, Nozaki K, Gon Y, Kikuchi H, Yodoi J. Redox control of neuronal damage during brain ischemia after middle cerebral artery occlusion in the rat: Immunohistochemical and hybridization studies of thioredoxin. J Cereb Blood Flow Metab 1998; 18: 206-214
23. Nakamura H, De Rosa S, Roederer M et al. Elevation of plasma thioredoxin levels in HIV-infected individuals. Int Immunol 1996; 8: 603-611.
24. Ahsan MK, Nakamura H, Tanito M, Yamada K, Utsumi H, Yodoi J. Thioredoxin-1 suppresses lung injury and apoptosis induced by diesel exhaust particles (DEP) by scavenging reactive oxygen species and by inhibiting DEP-induced downregulation of Akt. Free Radic Biol Med 2005; 39: 1549-1559.
25. Wada H, Hirata T, Decampos KN, Hitomi S, Slutsky AS. Effect of the combination of human thioredoxin and L-cysteine on ischemia-reperfusion injury in isolated rat lungs. Eur Surg Res 1995; 27: 363-370.
26. Gasdaska JR, Kirkpatrick DL, Montfort W et al. Oxidative inactivation of thioredoxin as a cellular growth factor and protection by a Cys73→Ser mutation. Biochem Pharmacol 1996; 52: 1741-1747.
27. Weichsel A, Gasdaska JR, Powis G, Montfort WR. Crystal structures of reduced, oxidized, and mutated human thioredoxins: Evidence for a regulatory homodimer. Structure 1996; 4: 735-751.
28. Andersen JF, Sanders DA, Gasdaska JR, Weichsel A, Powis G, Montfort WR. Human thioredoxin homodimers: Regulation by pH, role of aspartate 60, and crystal structure of the aspartate 60→asparagine mutant. Biochemistry 1997; 36: 13979-13988.
29. Ren X, Bjornstedt M, Shen B, Ericson ML, Holmgren A. Mutagenesis of structural half-cystine residues in human thioredoxin and effects on the regulation of activity by selenodiglutathione. Biochemistry 1993; 32: 9701-9708.
30. Tamaki H, Nakamura H, Nishio A et al. Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production. Gastroenterology 2006; 131: 1110-1121.
31. Amaral FA, Fagundes CT, Guabiraba R et al. The role of macrophage migration inhibitory factor in the cascade of events leading to reperfusion-induced inflammatory injury and lethality. Am J Pathol 2007; 171: 1887-1893.
32. Inomata Y, Tanihara H, Tanito M et al. Thioredoxin-1 suppresses choroidal neovascularization via interaction with complement factor H. Invest Ophthalmol Vis Sci 2008; 49: 5118-5125.
33. Le Brun PP, de Boer AH, Heijerman HG, Frijlink HW. A review of the technical aspects of drug nebulization. Pharm World Sci 2000; 22: 75-81.